Comprehensive Analysis of N6-Methyladenosine Modification Profiling in Diabetic Erectile Dysfunction

Area of Science:

• Molecular Biology
• Epigenetics
• Urology

Background:

• Diabetic erectile dysfunction (DMED) is a common complication of diabetes with limited therapeutic options.
• The role of RNA N6-methyladenosine (m⁶A) modification in DMED pathogenesis is not well understood.

Purpose of the Study:

• To investigate m⁶A modification patterns in DMED.
• To identify potential therapeutic targets for DMED based on m⁶A regulation.

Main Methods:

• Established a rat model of DMED using streptozotocin.
• Assessed erectile function, corpus cavernosum fibrosis, and RNA m⁶A levels.
• Utilized MeRIP-seq and RNA-seq to identify differentially methylated and expressed genes.

Main Results:

• DMED exhibited elevated RNA m⁶A levels and altered METTL14/METTL3 expression.
• Identified 2,789 m⁶A-associated genes, with key genes POSTN and LOX validated.
• Found that POSTN and LOX are linked to fibrosis and enriched in corpus cavernosum fibroblasts in DMED.

Conclusions:

• This study is the first to explore RNA m⁶A modification in DMED.
• Provides novel insights into DMED pathogenesis and identifies potential therapeutic targets.